

G-A-10					
제목	국문	Genetically Dibetic (ob/ob) Mice 에서 Zinc plus Cyclo(His-Pro)의 혈당저하 효과에 관한 연구			
	영문	Effects of Zinc plus Cyclo(His-Pro) on Clinical Signs of Diabetes in Genetically Dibetic (ob/ob) Mice			
저자 및 소속	국문	황인경 ¹ , 오차재 ² , 이동준 ² , 장준호 ² , 이수일 ¹ , 조병만 ¹ , Vay Liang W.Go ³ 부산대학교 의과대학 예방의학교실 ¹ , 부산대학교 의과대학 산업의학교실 ² , UCLA CENTER FOR HUMAN NUTRITION ³			
	영문	Inkyung Hwang ¹ , Chajae Oh ² , Dongjun Lee ² , Junho Jang ² , Suill Lee ¹ , Byungmann Cho ¹ , Vay Liang W.Go ³ <i>PREVENTIVE MEDICINE, COLLEGE OF MEDICINE, PUSAN NATIONAL UNIVERSITY¹, OCCUPATIONAL MEDICINE, COLLEGE OF MEDICINE, PUSAN NATIONAL UNIVERSITY², UCLA CENTER FOR HUMAN NUTRITION³</i>			
분야	보건관리 [기타]	발표자	황인경 [일반회원]	발표형식	포스터
진행상황	연구완료				
<p>1. 목적</p> <p>We have previously reported that cyclo(his-pro)(CHP) alleviated some symptoms of diabetes in streptozotocin-induced diabetic rats. In the present study, the acute and chronic effects of Zinc plus CHP on genetically diabetic (ob/ob) mice were determined.</p> <p>2. 방법</p> <p>To evaluate the acute effects of Zinc plus CHP on hyperglycemia, blood glucose levels in ob/ob mice and oral glucose tolerance (OGT) in lean and ob/ob mice (n= 4 each group) were determined after administration of CHP via gavage. To evaluate long-term effects of Zinc plus CHP, lean and ob/ob mice were treated with increasing doses (0, 0.5, 1.0, or 1.5 mg/L) of CHP plus zinc for three weeks (n=4 each). Postprandial blood glucose, fasting blood glucose, OGT, body weight, and intake of food and water were determined.</p> <p>3. 결과</p> <p>Blood glucose levels decreased and OGT improved immediately after gastric gavage with Zinc plus CHP in ob/ob mice, but not in lean mice. Similarly, three-week treatment with 1.0 mg CHP/L plus zinc significantly decreased postprandial and fasting blood glucose, OGT, and body weight gain in ob/ob mice, but not in lean mice.</p> <p>4. 고찰</p> <p>Zinc plus CHP is effective in decreasing blood glucose levels in genetically obese (ob/ob) mice. Therefore, this agent may be a useful anti-hyperglycemic agent for controlling obesity-related hyperglycemia.</p>					